Drugs / OT202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06435182 | Apr 2023 → Jan 2024 | dry eye syndrome | Ocumension Therapeutics (Shanghai) Co., Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-01-29 | Ocumension Therapeutics (Shanghai) Co., Ltd | Results 全球瞩目！欧康维视1类干眼新药OT-202临床研究成果在国际顶尖眼科期刊《Ophthalmology》发表 ocumension.com ↗
OT-202作为双效机制药物，对干眼体征和症状均有显著改善。 |
| 2025-11-04 | Ocumension Therapeutics (Shanghai) Co., Ltd | Results 全球瞩目！欧康维视1类干眼新药OT-202临床研究成果在国际顶尖眼科期刊《Ophthalmology》发表 ocumension.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-29 | Ocumension Therapeutics (Shanghai) Co., Ltd | 全球瞩目！欧康维视1类干眼新药OT-202临床研究成果在国际顶尖眼科期刊《Ophthalmology》发表 ocumension.com ↗ |
| 2025-11-04 | Ocumension Therapeutics (Shanghai) Co., Ltd | 全球瞩目！欧康维视1类干眼新药OT-202临床研究成果在国际顶尖眼科期刊《Ophthalmology》发表 ocumension.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OT202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06435182 ↗ |
| Route | Other | “into the conjunctival sac” NCT06435182 ↗ |